Jason Hier

The disconnect shows up most clearly between corporate and site teams in both R&D and manufacturing. A roadmap translates high-level plans into workstreams with owners and timing, so teams can see what needs to happen and when.

In one post, Jason Hier describes being surprised and disappointed by how disconnected some pharma organizations were, especially between corporate and site teams in both R&D and manufacturing.

Read original

Jason Hier’s target is not total agreement but “sufficiently aligned”: teams can see and connect the alignment relationships between the moving parts.

Cross-functional alignment means keeping R&D, compliance, manufacturing and market access moving together on one plan.

Read original

The remedy is for key stakeholders to select the “must haves” together in a visual, interactive format, building buy-in rather than imposing a ranking from above.

The named tool is a MoSCoW grid—must have, should have, could have and won’t have—with stakeholders placing initiatives on the shared grid together.

Read original

Spreadsheets and presentations are inadequate for tracking the move from discovery into development and from tech transfer into manufacturing; live visuals and current data let leaders steer proactively, reprioritize quickly and keep delivery tied to strategic goals.

The stated payoff is spotting risk early and reprioritizing quickly, rather than reacting after a handoff has gone wrong.

Read original · Original 2

A single source of truth offers a practical coordination fix rather than a culture program: when everyone sees the same picture, collaboration takes less effort.

A roadmap is the “missing link” connecting strategy to execution and increasing transparency across departments.

Read original

Tolerated items that cause no immediate pain accumulate, the argument goes, and seeing them together reveals connections and a strongly positive cause and effect. The stated intention is to have a business roadmap in place for the coming year.

Jason Hier describes walking a Pembrokeshire coastal path and resolving to update the business roadmap for 2026, asking whether current work is taking the business in the right direction.

The one reviewed piece that leaves life sciences behind draws on personal reflection and tags construction alongside pharma, biotech, R&D and manufacturing, suggesting the argument reaches beyond a single sector.

Read original

Start here for the clearest account of the roadmapping problem and solution, including specific methods and a named tool.

Jason Hier outlines two common failures in life sciences companies: research, regulatory, product and commercial goals are misaligned, causing delays and rework; and initiatives are not prioritized by strategic value, spreading resources thin.

• They explain how a strategic business roadmap addresses these issues by aligning functions, visualizing dependencies and bottlenecks, and applying a collaborative prioritization method such as a MoSCoW grid.
• They also describe their work at Roelto supporting life sciences organizations with SharpCloud-powered visual roadmaps.

For brands planning a campaign

For a consulting firm pitching roadmap workshops, this post offers a concrete framework—alignment, risk visualization and MoSCoW prioritization—that can be adapted into workshop modules. It also signals a partnership with SharpCloud, creating an opportunity for a content collaboration on practical prioritization techniques for pharma R&D and manufacturing audiences.

Start here for a concise case linking roadmaps to execution and cross-department transparency, and for a clear sense of the value proposition.

Jason Hier argues that life sciences organizations often struggle to connect strategy across corporate and site levels, especially in R&D and manufacturing.

• They present a roadmap as the missing link between strategy and execution—one that increases transparency and enables real-time progress monitoring.
• Strategy is the destination; the roadmap is the vehicle.

For brands planning a campaign

For a firm selling roadmap workshops, this post offers a simple metaphor and three clear benefits—connection, transparency and monitoring—for a workshop pitch. It also highlights the disconnect between corporate and site levels, a specific pain point for a content collaboration aimed at pharma executives.

Start here to see them apply their own advice, making the roadmapping approach more relatable and credible.

Jason Hier reflects on personal and business planning, noting that they often help clients connect silos but neglect their own business.

• They describe a walk in Pembrokeshire and the realization that they need to update their business roadmap for 2026.
• The post shows them applying the same roadmapping discipline they advocate, with reflection leading to action.

For brands planning a campaign

This post humanizes the roadmapping message and could support a content collaboration on practicing what you preach or year-end planning. Jason Hier shares a personal reflection, helping build trust with consultants and business leaders.

Jason Hier names two recurring failures: research, regulatory, product and commercial goals that are not aligned, and initiatives not prioritized against real strategic value, which spreads resources across underperforming work. The alignment target is "sufficiently aligned": not perfect agreement, but visible relationships between the moving parts.

Mapping dependencies between R&D, compliance, manufacturing and market access on one visual plan instead of tracking them across separate documents.

For brands planning a campaign

A firm selling strategy, portfolio or program-management services to pharma can commission content on alignment failure modes and how a shared roadmap exposes them—a topic this creator already argues in public and can discuss with concrete examples.

Examples: Source 1 · Source 2

The observation comes from pharma companies where corporate and site teams in both R&D and manufacturing operated disconnected. A roadmap is positioned as the link that turns high-level plans into clear, actionable workstreams with defined timing.

Translating strategy statements into workstreams with owners and sequencing, so teams can see what has to happen and when.

For brands planning a campaign

This is the sharpest content hook for a consulting brief on strategy-to-execution: a piece or webinar on why strategy stalls between corporate and site teams, drawing on the creator's account of where the disconnect shows up.

Examples: Source 1

There is always more work than budget or people allow, so key stakeholders should co-create the ranking in a visual, interactive format to build buy-in and support. The concrete tool named is a MoSCoW grid—must have, should have, could have, won't have.

Running prioritization sessions where stakeholders place initiatives on a shared grid, making selection visible and jointly owned.

For brands planning a campaign

The creator describes a roadmap workshop format in their posts, making a co-branded prioritization session or downloadable workshop kit a natural collaboration.

Examples: Source 1

The proposed remedy is one shared view for everyone, which the creator says makes collaboration less effortful. It is a practical coordination fix, not a cultural program.

Giving cross-functional teams the same live visual, so disagreement surfaces as a conflict in the plan rather than as missed handoffs.

For brands planning a campaign

Content for operations and program leaders can make the case for shared planning tools, drawing on the creator's experience with disconnected departments.

Examples: Source 1

The specific pain points are visibility into dependencies, gaps and bottlenecks, especially across discovery to development and tech transfer into manufacturing, and the difficulty of managing them with spreadsheets and presentations. The stated alternative is dynamic visuals and live data, letting leaders reprioritize quickly and keep delivery tied to strategic goals.

Visualizing dependencies and bottlenecks on a live plan to identify risks before they become costly delays.

For brands planning a campaign

This angle supports a risk-management or portfolio-visibility content series and gives a vendor of visual planning software a clear tie-in to the creator's existing narrative.

Examples: Source 1 · Source 2

The creator reflects on actions carried over for several years because they cause no immediate pain, and notes that addressing their connections together would be strongly positive. They spend their time helping clients find alignment while working in their own business rather than on it, and plan to have a business roadmap in place for the coming year.

Applying the same roadmap discipline to an annual personal and business review, asking whether current work is moving toward the required outcomes.

This post leaves life sciences behind, draws on personal reflection, and tags construction alongside pharma and biotech, showing that the message is pitched beyond one sector.

For brands planning a campaign

A seasonal planning campaign in late Q4 can use this angle; the broader sector framing also makes the creator relevant to audiences outside pharma.

Examples: Source 1

They build their arguments with operational details — which functions disconnect, where the pipeline breaks down, which tool is used — rather than statistics or research citations. Each closes with a direct call to action.

Problem framing, bullet points, a named tool or grid, and a brief invitation to discuss.

For brands planning a campaign

Brands should expect concise, opinion-led posts and workshop invitations, not data-heavy reports or long-form research. Collaborations should supply the evidence or data the creator's format lacks.

Examples: Source 1 · Source 2 · Source 3

The posts present Roelto as the business behind the roadmapping service and use “we” but do not state whether Hier owns the company or works there. Ask about their relationship to Roelto.

View example

SharpCloud is named as the delivery platform. Ask whether any sponsorship, reseller or partnership terms apply.

View example

Each uses a named framework — a roadmap for Ansems, the Digital Organism and digital thread for Jason Hier — to argue that making the connection is the hard part. Their posts also share a conference-and-community orientation, with Ansems speaking from a life science forum and Jason Hier examining disconnects between sites and corporate teams.

Ansems centers on AI, simulation, knowledge graphs and digital-twin architecture, framing the challenge as turning data into decisions at scale; their posts offer event recaps and framework explanations. Jason Hier focuses on planning and prioritization — dependencies, sequencing and who chooses the must-haves — and builds the argument with operational detail rather than technology architecture.

Read original · Original 2

Lewis makes the case directly in an acquisition post, calling for engineering, quality, automation, digital systems and operations to align around the same objectives.

Lewis covers the sector through industry news and corporate announcements, including deal roundups, restructuring, FDA leadership turnover and an acquisition integration. Jason Hier writes argument-led posts that diagnose internal problems and propose planning fixes.

Read original · Original 2

Cormier makes the case for partnerships between industry and academic medicine, and between manufacturers and clinicians.

Cormier writes as a regional advocate, using compiled funding figures and a decade of investment to argue that Rhode Island should attract and retain life sciences companies. Jason Hier focuses on alignment within a single organization and offers a planning method rather than an economic-development case.

Read original · Original 2

Ansems's posts give a named framework (the Digital Organism: Mind, Heart, Body, Soul) and specific arguments about AI as a context problem, trapped manufacturing capacity, Eroom's Law, and connecting scientific intent to equipment reality. This is a stronger match if the buyer is a manufacturing, digital, or R&D technology leader who wants a conceptual architecture and event-backed point of view rather than a collaborative prioritisation exercise.

The tradeoff is that Patrick Ansems's posts do not show the hands-on roadmap facilitation Jason Hier's posts describe, such as MoSCoW prioritisation, dependency mapping, corporate-site alignment, or a reusable workshop kit.

• Ansems's posts are more event- and framework-led, with references to Arvato Systems and Siemens Living Lab appearances.
• The firm would need to provide the workshop mechanics, prioritisation method, and client-facing exercises, and be ready for a more digital-manufacturing- and AI-heavy conversation than a general cross-functional alignment session.

Examples: Source 1 · Source 2

Lewis's posts show a regular industry-roundup format covering licensing, FDA leadership changes, layoffs, top-selling drugs, supply-security policy, and AI drug-design funding, plus a first-person account of the SimoTech acquisition aligning automation and digital manufacturing with project delivery, CQV, quality, and operational readiness. That fits a consulting firm that wants to reach pharma manufacturing, engineering, quality, and CQV leaders with timely sector updates and acquisition-integration commentary.

The tradeoff is that Dan Lewis's posts are closer to news and operational commentary than to a strategy-to-execution workshop.

• A collaboration would likely need the firm to build the interactive workshop and strategy-connection method, and the audience may be wider and more news-driven than the niche roadmap buyers Jason Hier addresses.
• Dan Lewis is also a better fit when the firm can move quickly on current events, because the news roundup format dates faster than a method-led post.

Examples: Source 1 · Source 2

Cormier's posts walk through Rhode Island's life sciences ecosystem with specific dollar figures across NIH awards, university gifts, manufacturing investment, incubators, and state facilities, and argue that retention of existing companies should sit alongside attraction. That is a strong fit for an economic development organization, a site-selection campaign, or a public-affairs collaboration with a place-based audience.

The tradeoff is that the content is geographically specific to Rhode Island and focused on ecosystem investment and policy, not on helping a pharma client connect corporate and site teams or run a roadmap workshop. If the firm's buyer is a global pharma R&D, manufacturing, quality, or commercial leader, ask for evidence of a cross-functional alignment method, prioritisation exercise, or R&D-to-manufacturing operating framework before choosing Bob Cormier; otherwise, the conversation may shift toward economic development and away from the firm's core strategy-to-execution offer.

Examples: Source 1 · Source 2